During a live event, Tian Zhang, MD, MHS, discussed options and recent trial data for treating metastatic hormone-sensitive ...

Early results from the TUSCANY trial highlight promising remission rates and safety for a new triplet therapy in treating ...

A groundbreaking study reveals ctDNA testing outperforms traditional imaging in predicting outcomes for large B-cell lymphoma ...

FDA endorses bexmarilimab for higher-risk myelodysplastic syndromes, paving the way for accelerated approval and promising ...

A systemic review of patient-reported outcome measures used in melanoma research and clinical practice reveals high ...

Patient dosing has continued to successfully escalate in an early-phase trial of a novel FSHR-targeting CAR T-cell therapy in ...

IMA203 showed an excellent safety profile and promising efficacy in solid tumors, leading to a new registration-directed clinical trial.

A panelist discusses how a man aged 82 years with good performance status presented with unexplained weight loss and abdominal pain, leading to a diagnosis of metastatic pancreatic adenocarcinoma with ...

A groundbreaking phase 3 study for lisaftoclax offers hope for first-line treatment of higher-risk myelodysplastic syndrome, ...

Jered Haddad transforms his cancer journey into a mission, cycling in Iceland to raise awareness and funds for multiple ...

The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for ...

FDA designates ifinatamab deruxtecan as a breakthrough therapy for extensive-stage small cell lung cancer, promising improved ...